Samsung BioLogistics has announced that it plans to expand its production facilities both domestically and abroad in line with the investment plan disclosed on the 31st. The company maintains its target share price of KRW 205 million while simultaneously advancing a “modality” diversification strategy and strengthening global manufacturing capabilities.
Through this investment, the company intends to secure about KRW 1.9 trillion. This amount will be used for new plant construction and completion of existing plants. In particular, it plans to build four to five new plants and complete six plants by year‑end, thereby expanding its production lineup.
In a prior announcement, the company had secured roughly KRW 1.9 trillion in 2022, allocating funds to finish four plants and expand five others within the same year. This has increased the likelihood of securing customers for most global pharmaceutical companies and established a strategy for entering new markets beyond existing production facilities.
Samsung BioLogistics also aims to strengthen cooperation with major partners such as Samsung Life Sciences and Samsung Engineering. With about KRW 2 trillion invested in 2022, it is expected that this round will be followed by large‑scale contracts. Accordingly, the company’s top share price for the year appears poised to rise roughly 79%.
(Article written by Lee Su-han, Kyeongdot.com reporter)